Using high-frequency rTMS to help reduce alcohol consumption in patients with alcohol use disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of high-frequency repetitive transcranial magnetic stimulation (rTMS) in reducing alcohol consumption among non-abstinent patients diagnosed with alcohol use disorder. The study aims to recruit adult participants who are willing to reduce their alcohol intake and have previously attempted to quit or cut down. Participants will receive either active rTMS or a placebo treatment, alongside assessments through questionnaires and breathalyzer tests to monitor their alcohol consumption. The goal is to provide a new treatment option that focuses on reducing consumption rather than requiring complete abstinence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* a person who has given his or her free, written and informed consent
* adult patient
* patient with mild to severe alcohol use disorder according to DSM-5 criteria
* voluntary patient to reduce alcohol consumption
* patient who has already made at least one attempt at alcohol withdrawal (failure or relapse), or at reducing consumption

Exclusion Criteria:

* person who is not affiliated to or not a beneficiary of national health insurance
* person subject to a legal protection measure (curatorship, guardianship)
* person subject to a legal safeguard measure
* pregnant, parturient or breastfeeding women
* adult unable to express consent
* patient of childbearing age with a positive pregnancy test at inclusion
* patient with an exhaled alcohol level \> 0 milligrams/litre inclusive
* patient with heavy alcohol consumption \< 6 days in the 4 weeks prior to inclusion (European Medicine Agency, 2010; one day with alcohol consumption of 60g or more for men and 40g for women)
* patient with an average alcohol consumption below the WHO average risk level in the 4 weeks prior to inclusion (WHO, 2000, less than or equal to 40g/day for men and 40g for women)
* patient being abstinent more than 5 days before inclusion
* patient with a CIWA (Clinical Institute Withdrawal Evaluation: assessment of the severity of alcohol withdrawal) score greater than or equal to 10 at inclusion
* Patient with concomitant treatment with disulfiram, acamprosate, topiramate, baclofen, naltrexone, and nalmefen (\< 1 month)
* Patient with a history or presence of pre-delirium tremens or delirium tremens
* Patient with a substance use disorder (DSM-5 criteria) with psychoactive substances other than tobacco and alcohol.
* Patient with acute psychiatric disorders requiring hospitalization and/or immediate adjustment of psychotropic medication
* Patient with severe depression, defined by a score of 24 or more on the Hamilton Depression Scale (HAM-D).
* Patient who has had a recent change (\< 1 month) in the prescription of psychotropic treatment
* Patient with severe and/or chronic psychiatric disorders, including schizophrenia, paranoia and bipolar disorders type I and II
* Patient with severe heart, kidney, liver or lung failure or other condition that the doctor believes could compromise the patient's participation in the study.
* Patient with a contraindication to the practice of rTMS; personal history of seizure, pacemaker, neurosurgical clips, carotid or aortic clips, heart valves, hearing aid, ventricular bypass valve, sutures with wires or staples, foreign bodies in the eye, shrapnel, other prosthesis or cephalic ferromagnetic material.
* Patient simultaneously participating in another therapeutic trial
* Patient employed by the investigator or trial site
* Patient who, according to the investigator, is unable to complete a consumption diary and follow up visits for 6 months
* Patient refusing to sign the "safety contract "\* specific to the study

Where it's running

• Chu Dijon Bourogne
  Dijon, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term mental health tracking for medical students

  This project will try to find what makes medical students more likely to develop depression by following cohorts of first-year health students over time and comparing them with peers who did not progress to the second year.

  Recruiting Centre Hospitalier Régional d'Orléans · Orléans, Loiret · NCT07305701

• BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for adults with alcohol use disorder

  This study will test whether BrainsWay Deep TMS can reduce heavy drinking in adults with moderate to severe alcohol use disorder compared with a sham procedure.

  Recruiting at 9 sites Brainsway · Tuscaloosa, Alabama and 10 other locations · NCT07216872

• How alcohol changes the social brain during paired interactions

  This study tests whether drinking alcohol changes brain activity and social bonding during conversations between pairs of regular social drinkers aged 21–30.

  Recruiting University of Illinois at Urbana-Champaign · Champaign, Illinois and 1 other locations · NCT07125534

• Cortical Excitability and DLPFC Structure in Healthy Adults Using TMS, EEG, and High-Field MRI

  This study tests how reproducible brain signals from transcranial magnetic stimulation relate to the anatomy of the left prefrontal cortex in healthy adults.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Marseille · NCT07071259

• Ketamine plus real-time fMRI neurofeedback for alcohol use disorder

  This trial will test whether ketamine combined with real-time fMRI neurofeedback helps adults with alcohol use disorder drink less.

  Recruiting Phase 2 Psychiatric University Hospital, Zurich · Zurich · NCT06969937

• Tirzepatide's effects on alcohol intake in patients with schizophrenia and alcohol use disorder

  This study is testing if the medication tirzepatide can help people with schizophrenia and alcohol use disorder drink less alcohol over six months.

  Recruiting at 2 sites Phase 2 Psychiatric Centre Rigshospitalet · Aalborg, Denmark and 1 other locations · NCT06939088

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.